Drugmaker fined by Spanish regulators $10M for 'excessive price' of rare disease drug
A company that has been under the microscope for drug pricing before has found itself fined by Spanish regulators.
Leadiant Biosciences has been fined €10.3 million ($10.6 million) by the Spanish regulators Comisión Nacional de Los Mercados y la Competencia (CNMC), after a massive price hike of its chenodeoxycholic acid (CDCA) compound, which is used to treat the rare disease cerebrotendinous xanthomatosis (CTX).
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
